Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.48

+0.7%

10:47 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (3971)	6/3/2001 7:52:00 PM
From: Miljenko Zuanic	Read Replies (1) of 52153

There is another (possible) weakness with Aberelix. Safety, immuno-toxicity. <<We observed some adverse reactions in patients during our abarelix depot studies, including allergic reactions and temporary and reversible elevation of some liver enzymes.>> A is chimeric, and long exposure may trigger anti-antibody. AMGN/PRCS did run third (toxicology) PIII trials, 12 months, but never disclose data. Few days ago I sold my small PRCS position because: 1) do not expect timely FDA respond on fast track NDA file, 2) concern about safety, 3)competition from ATIS formulation, and 4)negative from TAP (price pressure). This was preventive action, and may be premature. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next